Cargando…

The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy

BACKGROUND: Significant improvements in mortality among patients with non-small cell lung cancer (NSCLC) in the USA over the past two decades have been reported based on Surveillance, Epidemiology, and End Results (SEER) data. The timing of these improvements led to suggestions that they result from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramagopalan, Sreeram, Leahy, Thomas P., Ray, Joshua, Wilkinson, Samantha, Sammon, Cormac, Subbiah, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442434/ https://www.ncbi.nlm.nih.gov/pubmed/34521405 http://dx.doi.org/10.1186/s12916-021-02070-w

Ejemplares similares

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer
por: Ramagopalan, Sreeram V., et al.
Publicado: (2021)

The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE)
por: Leahy, Thomas P., et al.
Publicado: (2020)

Derivation of DO-BITS, a score for predicting success on Love Island: a retrospective, observational cohort study
por: Simpson, Alex, et al.
Publicado: (2020)

Can real-world data really replace randomised clinical trials?
por: Ramagopalan, Sreeram V., et al.
Publicado: (2020)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study
por: McDonald, Laura, et al.
Publicado: (2018)

Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
por: Wilkinson, Samantha, et al.
Publicado: (2021)

For what it's worth: the complex area of medicine value assessment
por: Ramagopalan, Sreeram V, et al.
Publicado: (2023)

Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
por: Popat, Sanjay, et al.
Publicado: (2022)

Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non–Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment
por: Ramagopalan, Sreeram V., et al.
Publicado: (2022)

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
por: Montalban, Xavier, et al.
Publicado: (2023)

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer
por: Popat, Sanjay, et al.
Publicado: (2022)

Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study
por: Leahy, Thomas Patrick, et al.
Publicado: (2023)

The value of innovation under value-based pricing
por: Moreno, Santiago G., et al.
Publicado: (2016)

Life after COVID-19: R WE going to help?
por: Ramagopalan, Sreeram V, et al.
Publicado: (2020)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10
por: Simpson, Alex, et al.
Publicado: (2022)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12
por: Bray, Ben, et al.
Publicado: (2023)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 11
por: Bray, Ben, et al.
Publicado: (2023)

Is Lamarckian evolution relevant to medicine?
por: Handel, Adam E, et al.
Publicado: (2010)

What is Next for the Genetics of Multiple Sclerosis?
por: Ramagopalan, Sreeram V., et al.
Publicado: (2011)

Multiple sclerosis: major histocompatibility complexity and antigen presentation
por: Ramagopalan, Sreeram V, et al.
Publicado: (2009)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13
por: Bray, Benjamin D, et al.
Publicado: (2023)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
por: Russano, Marco, et al.
Publicado: (2023)

Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers
por: Meunier, Aurelie, et al.
Publicado: (2023)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Using Twitter to investigate opinions about multiple sclerosis treatments: a descriptive, exploratory study
por: Ramagopalan, Sreeram, et al.
Publicado: (2014)

Decrease in rate of multiple sclerosis-related hospitalizations in Portugal
por: Pereira, Marta, et al.
Publicado: (2016)

Editorial: Environmental risk factors and inflammation in psychiatric and neurological disease
por: Meier, Ute-Christiane, et al.
Publicado: (2022)

The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy
por: Pan, Yuting, et al.
Publicado: (2023)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis
por: Foster, Corey C., et al.
Publicado: (2019)

Multiple Sclerosis
por: Ramagopalan, Sreeram, et al.
Publicado: (2011)

Sleep and BMI: Do (Fitbit) bands aid?
por: McDonald, Laura, et al.
Publicado: (2018)

Recording and treatment of premenstrual syndrome in UK general practice: a retrospective cohort study
por: Sammon, Cormac J, et al.
Publicado: (2016)

The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy
por: Gou, Miaomiao, et al.
Publicado: (2021)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Real-world data and the patient perspective: the PROmise of social media?
por: McDonald, Laura, et al.
Publicado: (2019)

Access in all areas? A round up of developments in market access and health technology assessment: part 1
por: Gilardino, Ramiro, et al.
Publicado: (2023)

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma
por: Landuzzi, Lorena, et al.
Publicado: (2023)

Risk of fractures in patients with multiple sclerosis: record-linkage study
por: Ramagopalan, Sreeram V, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ekijjgv8hjv889cf64t625j05p